FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3097170216> ?p ?o ?g. }

• W3097170216 endingPage "14" @default.
• W3097170216 startingPage "14" @default.
• W3097170216 abstract "Introduction: The ever-rising cost of the oncology prescription drugs not only impacts the global cost of cancer care, but also affects the individual patient's financial toxicity, compliance, and outcomes. In safety-net setting, where the quality and quantity of care can be limited by the institution's budget, Prescription Assistance Programs (PAPs) are critical to patient care. Navigating the application process for these programs can be challenging for patients, especially for minorities and those with low health literacy. We looked at a pharmacy-run service for PAP enrollment at our safety-net hospital for patients diagnosed with chronic myeloid leukemia (CML). Methods: A total of 113 patients with CML who were receiving care at Parkland Health and Hospital System in Dallas, Texas, between January 2018 and December of 2019 were identified. Our pharmacy-run PAP service utilizes medication access technicians to complete PAP application packets for oncology patients. Patient records were reviewed to identify the payor mix, the choice of tyrosine kinase inhibitor (TKI), and number of prescriptions filled during the study period. Cost estimates are based on best advertised price for the individual drugs. For imatinib, cost estimate was based on the generic form. Results: Of the 113 CML patients, 78 did not have insurance. The majority of patients were Hispanic (61%); 19% were Black. In 62 patients (55%), English was not the primary language. TKIs used in first-line (insured vs uninsured) were: imatinib (49% vs 46%), dasatinib (31% vs 49%) and nilotinib (11% vs 5%). All uninsured patients were enrolled in Prescription Assistance Programs (PAP). The average time from diagnosis to application approval by the pharmaceutical companies was 23 days. Patients on average received the drug shipment 7 days after application approval. Uninsured patients received a total of 623 months' supply of their TKIs during the study period. Of these, only 7 were covered by the institution, most commonly to allow timely initiation of treatment while the PAP application was being processed. The estimated medication cost for the uninsured patients over the study period was $5.4m, of which $93k (2%) was covered by the institution. Conclusion: Our pharmacy-run PAP service allowed for rapid enrollment of all uninsured patients in pharmaceutical free drug programs and significantly reduced the cost of CML care for the institution. An expansion of this service to allow better utilization of copay assistance programs for insured patients can impact the financial toxicity associated with TKIs and is currently being planned. Disclosures No relevant conflicts of interest to declare." @default.
• W3097170216 created "2020-11-09" @default.
• W3097170216 creator A5008905848 @default.
• W3097170216 creator A5032510985 @default.
• W3097170216 creator A5040283964 @default.
• W3097170216 creator A5049423872 @default.
• W3097170216 date "2020-11-05" @default.
• W3097170216 modified "2023-10-18" @default.
• W3097170216 title "Impact of Pharmaceutical Prescription Assistance Programs on the Care of Patients with Chronic Myeloid Leukemia in a Safety Net Hospital" @default.
• W3097170216 doi "https://doi.org/10.1182/blood-2020-143128" @default.
• W3097170216 hasPublicationYear "2020" @default.
• W3097170216 type Work @default.
• W3097170216 sameAs 3097170216 @default.
• W3097170216 citedByCount "0" @default.
• W3097170216 crossrefType "journal-article" @default.
• W3097170216 hasAuthorship W3097170216A5008905848 @default.
• W3097170216 hasAuthorship W3097170216A5032510985 @default.
• W3097170216 hasAuthorship W3097170216A5040283964 @default.
• W3097170216 hasAuthorship W3097170216A5049423872 @default.
• W3097170216 hasBestOaLocation W30971702161 @default.
• W3097170216 hasConcept C104863432 @default.
• W3097170216 hasConcept C126322002 @default.
• W3097170216 hasConcept C159110408 @default.
• W3097170216 hasConcept C160735492 @default.
• W3097170216 hasConcept C162324750 @default.
• W3097170216 hasConcept C194828623 @default.
• W3097170216 hasConcept C2426938 @default.
• W3097170216 hasConcept C2776291444 @default.
• W3097170216 hasConcept C2777413986 @default.
• W3097170216 hasConcept C2777583451 @default.
• W3097170216 hasConcept C2778729363 @default.
• W3097170216 hasConcept C2778858636 @default.
• W3097170216 hasConcept C2779457091 @default.
• W3097170216 hasConcept C50522688 @default.
• W3097170216 hasConcept C512399662 @default.
• W3097170216 hasConcept C71924100 @default.
• W3097170216 hasConceptScore W3097170216C104863432 @default.
• W3097170216 hasConceptScore W3097170216C126322002 @default.
• W3097170216 hasConceptScore W3097170216C159110408 @default.
• W3097170216 hasConceptScore W3097170216C160735492 @default.
• W3097170216 hasConceptScore W3097170216C162324750 @default.
• W3097170216 hasConceptScore W3097170216C194828623 @default.
• W3097170216 hasConceptScore W3097170216C2426938 @default.
• W3097170216 hasConceptScore W3097170216C2776291444 @default.
• W3097170216 hasConceptScore W3097170216C2777413986 @default.
• W3097170216 hasConceptScore W3097170216C2777583451 @default.
• W3097170216 hasConceptScore W3097170216C2778729363 @default.
• W3097170216 hasConceptScore W3097170216C2778858636 @default.
• W3097170216 hasConceptScore W3097170216C2779457091 @default.
• W3097170216 hasConceptScore W3097170216C50522688 @default.
• W3097170216 hasConceptScore W3097170216C512399662 @default.
• W3097170216 hasConceptScore W3097170216C71924100 @default.
• W3097170216 hasIssue "Supplement 1" @default.
• W3097170216 hasLocation W30971702161 @default.
• W3097170216 hasOpenAccess W3097170216 @default.
• W3097170216 hasPrimaryLocation W30971702161 @default.
• W3097170216 hasRelatedWork W1974135663 @default.
• W3097170216 hasRelatedWork W2008269670 @default.
• W3097170216 hasRelatedWork W2022079104 @default.
• W3097170216 hasRelatedWork W2041884123 @default.
• W3097170216 hasRelatedWork W2055128302 @default.
• W3097170216 hasRelatedWork W2314672328 @default.
• W3097170216 hasRelatedWork W4225285109 @default.
• W3097170216 hasRelatedWork W4250194358 @default.
• W3097170216 hasRelatedWork W54919303 @default.
• W3097170216 hasRelatedWork W2184736871 @default.
• W3097170216 hasVolume "136" @default.
• W3097170216 isParatext "false" @default.
• W3097170216 isRetracted "false" @default.
• W3097170216 magId "3097170216" @default.
• W3097170216 workType "article" @default.